ACE-16229210

N/A

Report date: 2024/07/10 11:08:20
NME

Base Information

Drug NameACE-16229210
Drug Alias NameACE-16229210ACE16229210
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 2 inhibitors
TargetsFibroblast growth factor receptor 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAcerand Therapeutics (Shanghai) Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAcerand Therapeutics (Shanghai) Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A